LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Затворен

0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.32

Максимум

0.32

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.9M 86M
Предишно отваряне	0.32
Предишно затваряне	0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.12.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Nike, Cassava Sciences, KB Home

18.12.2025 г., 23:51 ч. UTC

Печалби

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18.12.2025 г., 23:39 ч. UTC

Значими двигатели на пазара

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18.12.2025 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18.12.2025 г., 21:40 ч. UTC

Печалби

Nike Sales Tick Up, But China Weakness Persists

18.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18.12.2025 г., 23:37 ч. UTC

Пазарно говорене

Печалби

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18.12.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18.12.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18.12.2025 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18.12.2025 г., 22:58 ч. UTC

Придобивния, сливания и поглъщания

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18.12.2025 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18.12.2025 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18.12.2025 г., 22:55 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:59 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

18.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

18.12.2025 г., 21:35 ч. UTC

Печалби

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18.12.2025 г., 21:31 ч. UTC

Печалби

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Greater China Rev Down 17% >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q EPS 53c >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Apparel Rev $3.91B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Equipment Rev $550M >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q N Amer Rev $5.63B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Footwear Rev $7.66B >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18.12.2025 г., 21:15 ч. UTC

Печалби

Nike 2Q Greater China Rev $1.42B >NKE

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.